ISLAMABAD: Artificial intelligence (AI) is rapidly transforming the global pharmaceutical industry, and experts say Pakistan must embrace this revolution to compete in advanced markets. AI-driven tools are now cutting years off the drug discovery process, improving clinical trial accuracy, and ensuring compliance with international quality standards.
Jim Harris, a Canadian expert in digital innovation, will share insights on how machine learning and advanced analytics are reshaping medicine development, offering new hope for faster and more precise treatments. “Artificial intelligence is no longer experimental — it is already shaping how medicines are discovered, tested, and delivered,” said Dr Kaiser Waheed, Chairman of the upcoming Pakistan Pharma Summit. “For Pakistan, adopting AI will be as vital as meeting global standards if we want to build trust internationally.”
Industry analysts believe that with Pakistan’s pharmaceutical exports hitting a record $457 million in FY25 a 34% surge and the highest in two decades, the country is well-positioned to scale further if it integrates AI into its manufacturing and regulatory practices. Experts also highlight that AI can help predict risks, minimize human error, and strengthen compliance with benchmarks set by WHO, PIC/S, and MHRA.
The debate will unfold at the 8th Pakistan Pharma Summit and the 4th Pharma Export Summit & Awards (PESA 2025) on September 24 in Islamabad. The program will also feature leading voices on regulatory policy, quality culture, and global standards, concluding with the PESA Awards to honor achievements in exports and compliance.
